Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Swann

MOHS-Micrographic Surgery Springfield, MO Medical Doctor

NPI 1972607158 CMS profile 89170

3850 S National Ave, Suite 705, Springfield, MO 65807

Open in the dashboard

General payments

$5,938

163 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Swann of Springfield, MO is reported in the CMS Open Payments database as having received $5,938 across 163 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of MOHS-Micrographic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,716 36
2024 General $1,035 41
2023 General $364 12
2022 General $828 24
2021 General $766 20
2020 General $88 6
2019 General $1,140 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Swann
  • MOHS-Micrographic Surgery median
  • Middle half of MOHS-Micrographic Surgery
  • National median

In program year 2025, general payments to Michael Swann were reported at $1,716. Among 1,077 MOHS-Micrographic Surgery profiles paid that year, the median was $465 and the middle half received between $145 and $1,066.

Show as a table
Year Michael Swann MOHS-Micrographic Surgery median Middle half National median
2019 $1,140 $316 $106–$785 $163
2020 $88 $162 $68–$412 $114
2021 $766 $243 $87–$654 $132
2022 $828 $300 $102–$887 $149
2023 $364 $364 $125–$1,010 $160
2024 $1,035 $445 $142–$1,108 $164
2025 $1,716 $465 $145–$1,066 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Allergan Inc. $1,284 22 payments
  2. AbbVie, Inc. $1,182 27 payments
  3. Merz North America, Inc. $500 1 payment
  4. Sun Pharmaceutical Industries Inc. $262 6 payments
  5. Revance Therapeutics, Inc. $248 5 payments
  6. Biofrontera Inc. $232 11 payments
  7. Kerecis Limited $224 3 payments
  8. Organogenesis Inc. $170 8 payments
  9. Genzyme Corporation $158 7 payments
  10. Organon LLC $150 1 payment
  11. Other $1,529 72 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,278 142 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,580 19 payments
  3. Education $80 2 payments
Products named General payments · program years 2019–2025
  1. Xeomin $500 1 payment
  2. DAXXIFY $248 5 payments
  3. XEPI $232 11 payments
  4. RINVOQ $226 8 payments
  5. Kerecis Omega3 SurgiClose $224 3 payments
  6. BF-RhodoLED $187 9 payments
  7. Kerecis Omega3 Marigen $175 2 payments
  8. BOTOX $164 2 payments
  9. Erivedge $164 11 payments
  10. AMELUZ $154 7 payments
  11. Other $3,092 116 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

415

Median for Micrographic Dermatologic Surgery: 314

Drug cost

$3,409

Median for Micrographic Dermatologic Surgery: $3,836

Branded share of claims

12%

Median for Micrographic Dermatologic Surgery: 1.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cephalexin Generic 250 $1,628
Minocycline Hcl Generic 15 $403
Triamcinolone Acetonide Generic 24 $377
Ketoconazole Generic 29 $354
Erythromycin Erythromycin Base Brand 17 $190
Mupirocin Generic 21 $135
Valacyclovir Valacyclovir Hcl Brand 22 $115
Levofloxacin Generic 14 $107
Doxycycline Hyclate Generic 12 $73
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 11 $27

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 366 Part D prescribers listed as Micrographic Dermatologic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 127 billing codes

Paid by Medicare

$2,170,846

Of which drugs: $178,200

Medicare patients

2,585

Average age 75

Services billed

83,005

1,384 women, 1,201 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 46%
Ischemic heart disease 22%
Diabetes 21%
Chronic kidney disease 21%
Atrial fibrillation 16%
Cancer 16%
Depression 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg J7345 Office 107 64,000 $83,757
Affinity, per square centimeter Q4159 Office 12 103 $26,901
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 19 25 $19

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DAXXIFY
  • REVANCE THERAPEUTICS, INC. $202
$202 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $148
$148 — —
SKYRIZI
  • AbbVie, Inc. $101
$101 — —
TREMFYA
  • Janssen Biotech, Inc. $64
$64 — —
RINVOQ
  • AbbVie, Inc. $47
$47 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

163 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other MOHS-Micrographic Surgery in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record